Dr. Miguel Angel Materin, MD

Dr. Materin practices at Duke University Hospital in Durham, North Carolina, part of Duke University.

Dr. Materin's NPI, 1528292679, was assigned on May 5, 2009. Dr. Materin holds Connecticut license 52842.

Dr. Materin's primary practice is Duke University Hospital, at 2301 Erwin Rd, Durham, NC 27705 in Durham County. The practice phone is (919) 684-8111.

Dr. Materin's primary practice is Duke University Hospital in Durham, North Carolina, part of Duke University. The medical group on file is Duke Health Integrated Practice. Dmand AI also links Dr. Materin to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Materin practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Materin's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Materin is licensed in Connecticut.

CMS data shows 2,803 Medicare services from Dr. Materin across 13 procedure codes in 2024, for 562 Medicare patients. Medicare paid $140,826 for them.

CMS counts 562 Medicare patients who saw Dr. Materin in 2024. The largest group is 65 to 74, with 259 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 2% are also on Medicaid. Their average risk score is 1.13, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Materin's median patient age at 70, with 58% women.

In 2024, Dr. Materin wrote 13 Medicare Part D claims. Every claim was for a generic drug. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $1,487 in total drug cost. In 2020, CMS named 15 claims across 1 drug.

Dr. Materin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 52 papers to Dr. Materin, published from 2012 to 2025. 2019 was the busiest year, with 5. The most frequent topics are Melanoma, Uveal Neoplasms and Retinal Neoplasms. Dr. Materin has published most often in Ocul Oncol Pathol. Dr. Materin's most frequent co-authors are Avni Patel Finn, MBA, MD, Robert James House, MD and Wajiha Jurdi Kheir, MD.

CMS Open Payments shows 10 general payments to Dr. Materin from 8 drug and device companies from 2017 to 2025. Education speaker fees make up the largest share, 63% of the total. Carl Zeiss Meditec, Inc. paid the most, $2,742.